Electromed, Inc. Hits New 52-Week High of $38.99, Up 458%

Electromed, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 38.99 on May 21, 2026. This achievement marks a remarkable increase in the stock's performance, with a one-year gain of 458.32%, significantly outpacing the S&P 500's performance of 27.39% during the same period. The company's market capitalization stands at USD 197 million, reflecting its position within the microcap category. Electromed's price-to-earnings (P/E) ratio is currently at 22.00, indicating a valuation that is in line with its growth trajectory. Additionally, the company maintains a return on equity of 20.11%, showcasing its ability to generate profits from shareholders' equity. With a 52-week low of USD 17.73, the stock's recent performance highlights a strong upward trend, underscoring Electromed's potential within the competitive landscape of the pharmaceuticals and biotechnology industry.